Novartis Ag (NVS) Operating Expenses (2009 - 2026)

Novartis Ag has disclosed Operating Expenses across 18 years of filings, most recently posting -$6.1 billion for Q2 2026.

• In Q2 2026, Operating Expenses rose 1.31% year-over-year to -$6.1 billion; the TTM figure through Jun 2026 stood at -$29.8 billion (up 10.64% YoY), while the FY2025 annual figure was -$24.4 billion, down 8.23% from the prior year.
• Operating Expenses came in at -$6.1 billion for Q2 2026 at Novartis Ag, down from -$5.9 billion in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of -$5.3 billion in Q1 2024 to a low of -$17.9 billion in Q4 2023.
• Average Operating Expenses over 5 years is -$7.9 billion, with a median of -$6.0 billion recorded in 2022.
• Year-over-year, Operating Expenses slumped 32.67% in 2022 and climbed 28.64% in 2025.
• Over 5 years, Operating Expenses stood at -$16.0 billion in 2022, then slipped by 11.97% to -$17.9 billion in 2023, then advanced by 9.13% to -$16.2 billion in 2024, then rose by 28.64% to -$11.6 billion in 2025, then surged by 47.49% to -$6.1 billion in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were -$6.1 billion in Q2 2026, -$5.9 billion in Q1 2026, and -$11.6 billion in Q4 2025.